Stock Events

Stock Events

Cogent Biosciences 

$33.39
44
+$0+0% Monday 00:59

Statistics

Day High
33.39
Day Low
33.39
52W High
-
52W Low
-
Volume
8
Avg. Volume
-
Mkt Cap
5.42B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.61
-0.57
-0.54
-0.5
Expected EPS
-0.532603
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-657.87MNet Income

Analyst Ratings

$47.63Average Price Target
The highest estimate is 67.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COGT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and molecular therapies for cancer and other diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for cancer, directly competing in some of the same therapeutic areas as Cogent.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic diseases, competing in the rare disease space with Cogent.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other genetic disorders, areas where Cogent could potentially compete.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing directly in Cogent's focus area of genetic-driven diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi (RNA interference) therapies for genetic diseases, a competing technology in the genetic disease treatment space.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing, a form of gene editing, presenting direct competition in the genetic disease treatment market.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including treatments for genetic disorders, competing in the same therapeutic areas as Cogent.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the genetic and rare disease market similar to Cogent.

About

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US19240Q2012

Listings

BOATS
BOATS
COGT.BOATS
XNAS
US
COGT

0 Comments

Share your thoughts

FAQ

What is Cogent Biosciences stock price today?▼
The current price of COGT.BOATS is $33.39 USD — it has increased by +0% in the past 24 hours. Watch Cogent Biosciences stock price performance more closely on the chart.
What is Cogent Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cogent Biosciences stocks are traded under the ticker COGT.BOATS.
What is Cogent Biosciences market cap?▼
Today Cogent Biosciences has the market capitalization of 5.42B
When is the next Cogent Biosciences earnings date?▼
Cogent Biosciences is going to release the next earnings report on May 12, 2026.
What were Cogent Biosciences earnings last quarter?▼
COGT.BOATS earnings for the last quarter are -0.61 USD per share, whereas the estimation was -0.58 USD resulting in a -6.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cogent Biosciences revenue for the last year?▼
Cogent Biosciences revenue for the last year amounts to 0 USD.
What is Cogent Biosciences net income for the last year?▼
COGT.BOATS net income for the last year is -657.87M USD.
When did Cogent Biosciences complete a stock split?▼
Cogent Biosciences has not had any recent stock splits.